Adriaenssens E, Dumont L, Lottin S, Bolle D, Leprêtre A, Delobelle A, Bouali F, Dugimont T, Coll J, Curgy J J
Centre de Biologie Cellulaire, Université des Sciences et Technologies de Lille, Vileneuve d'Ascq, France.
Am J Pathol. 1998 Nov;153(5):1597-607. doi: 10.1016/S0002-9440(10)65748-3.
In a previous study we described the expression of the H19 gene by in situ hybridization (ISH) in normal breast and in benign or malignant breast tumors (Dugimont T, Curgy JJ, Wernert N, Delobelle A, Raes MB, Joubel A, Stehelin D, Coll J: Biol Cell 1995, 85:117-124). In the present work, 1) we extend the previous one to a statistically useful number of adenocarcinomas, including 10 subclasses, 2) we provide information on the precise ISH localization of the H19 RNA by using, on serial tissue sections, antibodies delineating specifically the stromal or the epithelial component of the breast, and 3) we consider relationships between the H19 gene expression and various clinicopathological information as tumor values (T0 to T4), grades, steroid receptors, lymph node status, and molecular features as the p53 gene product and the Ki-67/MIB1 protein, which is specific to proliferating cells. Data indicate that 1) in 72.5% of studied breast adenocarcinomas an overall H19 gene expression is increased when compared with healthy tissues, 2) the H19 gene is generally overexpressed in stromal cells (92.2%) and rarely in epithelial cells (2.9% only), 3) an up-regulation of the H19 gene is significantly correlated with the tumor values and the presence of both estrogen and progesterone receptors, and 4) at the cellular level, the H19 gene demonstrates an independent expression versus accumulation of both the p53 protein and the Ki-67/MIB-1 cell-cycle marker.
在之前的一项研究中，我们通过原位杂交（ISH）描述了H19基因在正常乳腺以及良性或恶性乳腺肿瘤中的表达情况（Dugimont T，Curgy JJ，Wernert N，Delobelle A，Raes MB，Joubel A，Stehelin D，Coll J：《生物细胞》，1995年，85卷：117 - 124页）。在本研究中，1）我们将之前的研究扩展至具有统计学意义数量的腺癌，包括10个亚类；2）通过在连续组织切片上使用特异性描绘乳腺基质或上皮成分的抗体，我们提供了H19 RNA精确ISH定位的信息；3）我们考虑了H19基因表达与各种临床病理信息之间的关系，如肿瘤值（T0至T4）、分级、类固醇受体、淋巴结状态以及分子特征，如p53基因产物和增殖细胞特异性的Ki - 67/MIB1蛋白。数据表明：1）在72.5%的研究乳腺腺癌中，与健康组织相比，H19基因的整体表达增加；2）H19基因通常在基质细胞中过度表达（92.2%），而在上皮细胞中很少表达（仅2.9%）；3）H19基因的上调与肿瘤值以及雌激素和孕激素受体的存在显著相关；4）在细胞水平上，H19基因的表达与p53蛋白和Ki - 67/MIB - 1细胞周期标记物的积累无关。
